Non-Small Cell Lung Cancer
Conditions
Keywords
celgene, cc-5013, NSCLC, CC5013, Revlimid, Non-Small Cell Lung Cancer
Brief summary
Subjects who qualify will receive single agent lenalidomide once daily on days 1-21 of 28 day cycles. Subjects will continue until disease progression is documented.
Interventions
DRUGCC-5013
Sponsors
Prologue Research International
Celgene Corporation
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Understand and voluntarily sign an informed consent form. 2. Age \>or = to 18 years at the time of signing the informed consent form 3. Able to adhere to the study visit schedule and other protocol requirements 4. Must have a histologically confirmed diagnosis of non small cell lung cancer that has recurred following at least two prior regimens. Those regimens must have contained both a platinum compound and a taxane either sequentially or in combination 5. Subjects must have measurable disease on cross sectional imaging that is at least 2 cm in the longest diameter. 6. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 (see Appendix II). 7. Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy test within 7 days of starting study drug. In addition, sexually active WCBP must agree to use adequate contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) while on study drug. WCBP must agree to have pregnancy tests every 4 weeks while on study drug (every 14 days for women with irregular cycles) and 4 weeks after the last dose of study drug.
Exclusion criteria
1. Any of the following laboratory abnormalities: 1. Absolute neutrophil count (ANC) \<1,500 cells/mm3 (1.5 x 109/L) 2. Platelet count \<100,000/mm3 (100 x 109/L) 3. Serum creatinine \>2.5 mg/dL (221 mmol/L) 4. Serum SGOT/AST or SGPT/ALT \>5.0 x upper limit of normal (ULN) 5. Serum total bilirubin \>2.0 mg/dL (34 mmol/L) 2. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study. 3. Prior history of malignancies other than non-small cell lung cancer (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the subject has been free of the disease for \> or = to 1 year. 4. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form. 5. Pregnant or lactating females. 6. Prior \> or = grade 3 allergic reaction/hypersensitivity to thalidomide. 7. Prior \> or = grade 3 rash or any desquamating (blistering) rash while taking thalidomide. 8. Prior use of lenalidomide. 9. Use of any standard/experimental anti-cancer drug therapy within 28 days of the initiation of study drug therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the activity of lenalidiomide in recurrent non-small cell lung cancer. Activity will be assessed by measuring the response rate, tumor control rate, and time to tumor progression. | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the safety of lenalidomide monotherapy as treatment for subjects with recurrent non-small cell lung cancer. | — |
Countries
United States
Outcome results
None listed